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ABSTRACT 
 
HIV is a prominent infection in society and its health implications are seen in the 
paediatric wards daily. Despite its multi-system effect on the body, it particularly 
results in many respiratory infections. Effective understanding of the disease profile 
and management of patients with HIV relies on correct statistics and proper use of 
resources. 
Since the introduction of anti-retrovirals in 2004 in South Africa, the impact of 
HIV/AIDS on respiratory disease needs to be re-evaluated. The purpose of the study 
is to understand the disease profile of children with HIV/AIDS with regard to the 
presence of respiratory conditions with which they present, the need for chest 
physiotherapy and their health status.  
Of the 125 patients recruited in this study 55% were boys, average age was 20.55 
months (SD= 23.64), average length of hospital stay of 2 ½ weeks (mean=18.76, 
SD=19.19), 80% discharged and 9.6% died. The most common respiratory 
conditions presented included bacterial pneumonia (66.4%), tuberculosis (48%) and 
pneumocystis jirovecii pneumonia (23.2%). The least common condition was 
lymphoid interstitial pneumonitis (4.8%).  Two thirds of the children (68.8%) 
presented with a high burden of disease. Physiotherapy treatment was indicated for 
96% of the patients mainly due to excess secretions and poor air entry. About forty 
percent (40.8%) of children were taking anti-retrovirals with an average length of use 
of 9.81 months (SD=11.61). Three out of four (75%) mothers were not involved in a 
PMTCT program. The analysis of immune status revealed a mean CD4 percentage 
17.33% (SD=10.96), CD4 absolute 631.36 cell/mm3 (SD=610.36) and viral load 2.6 
million copies /ml (SD=9.08 million copies/ml). 
 
A higher burden of disease was related to the use of anti-retrovirals, a lower 
immunity, female patients, longer length of hospital stay and incidences of mortality 
occuring at later periods of hospital stay.  
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Results of this study highlight the characteristics of respiratory disease burden 
among children with HIV in a South African setting in a post HAART era. 
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CHAPTER ONE 
Introduction 
1.1 Introduction 
 
This chapter discusses the background of the study and its significance, statement of 
the problem, the research questions, the purpose and objectives of the study, 
definition of terms used and an overview of the remaining chapters of the study. 
 
Physiotherapists practising in the paediatric field observe many patients infected by 
HIV/AIDS. This disease contributes to the incidence of many other opportunistic 
infections of which those respiratory in nature, are the most common. Respiratory 
disease remains a major cause of morbidity and mortality amongst HIV-infected 
children (Zar, 2008).  
 
According to the UNICEF global report in 2006, South Africa had the sixth highest 
prevalence of HIV in the world, later reporting in 2008 that South Africa has the 
highest incidence in the world with an estimated five point seven million people living 
with the disease - 25% of the Sub-Sahara-African statistics (UNAIDS, 2009). The 
2008 reports mention that of two point one million children infected worldwide, Sub-
Saharan Africa accounts for one point eight million of those.  An estimated 240 000 
children aged zero to fourteen were living with HIV in South Africa in 2005 according 
to statistics calculated by UNICEF (2010). 
 
The impact of HIV/AIDS on the health system is immense, hence it is of particular 
value to our country and to the physiotherapy profession to conduct research in this 
field. This study has determined the distribution of respiratory conditions among 
children with HIV/AIDS and their indication for physiotherapy as an in-hospital 
service. There are relevant factors which influence a HIV positive child’s health 
status including the use of anti-retrovirals, the CD4 count and viral loads, age, 
gender and length of hospital stay. These factors have been investigated to 
determine their influence on the burden of respiratory disease. 
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1.2 Background 
 
HIV/AIDS is a prominent disease that is observed within the South African health 
care environment on a daily basis. The disease in South Africa is defined as being 
hyper-endemic due to the high rate of HIV prevalence and the modes of HIV 
transmission of which mother-to-child transmission is the major cause of childhood 
infection (UNAIDS, 2010).  
 
Zar & Mulholland reported in 2003 that of more than one point five million HIV 
infected children, 90% will develop a respiratory illness sometime in the course of 
their HIV condition. In contrast, in developed countries, early diagnosis of HIV 
infection in infants, and use of pneumocystis jirovecii prophylaxis, and highly active 
anti-retroviral therapy (HAART) have led to a substantial decline in HIV associated 
respiratory infections (Zar, 2008). The management of HIV has made progress in 
South Africa and thus, the incidence of acute and opportunistic respiratory infections 
has declined while HIV-associated chronic lung disease has increasingly emerged 
(Zar, 2008). Respiratory disease in children infected with HIV/AIDS thus remains 
pertinent.  
 
1.2.1 Incidence of respiratory disease 
 
The incidence of acute pneumonia is much higher in HIV infected than 
uninfected children (aMadhi et al, 2000) and chronic lung diseases are much 
more common owing to a wider range of pulmonary diseases (Graham, 
2005). Literature reiterates that pneumocystis jirovecii pneumonia (PJP) is by 
far the most common opportunistic infection and serves as a HIV marker and 
many other studies have shown that PJP, cytomegalovirus (CMV), 
mycobacterium avium complex (MAC) and pulmonary tuberculosis (PTB) are 
among the most common opportunistic infections (Parker et al, 1998). The 
probability of developing PJP rises markedly as the CD4 count falls below 
200cells/mm3 (Lubis et al, 2003), however the use of HAART may decrease 
its incidence up to 86-100% according to Nesheim et al (2007). Lymphoid 
interstitial pneumonitis (LIP) is a condition which, despite its prevalence, 
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receives little attention. In children with HIV infection, LIP has been 
designated as an AIDS-defining illness by the US Center for Disease Control 
and Prevention (1994). A study done by Gona et al (2006) established that 
bacterial pneumonia and lymphoid interstitial pneumonitis have a prevalence 
of 25% and 12% respectively. Pulmonary infection may develop chronicity 
illustrated by the significant occurrence of bronchiectasis in children with AIDS 
particularly in children developing LIP, recurrent pneumonia and unresolved 
pneumonia (Sheikh et al, 1997).   
 
1.2.2 Influence of other factors on the burden of respiratory disease 
There are many other factors which may contribute towards the prevalence of 
respiratory conditions including age and health status. In the pre-HAART era 
the 0-3 year old group had the highest incidence of a first opportunistic 
infection (87%), whereas in the post-HAART era this was found in the 0-7 
year old group (33%), in a study completed by Nesheim et al (2007). Graham 
(2007) and Gona et al (2006) support this trend as survival rates have 
increased with improved treatment strategies.  
Health status may be evaluated through CD4 count and viral load testing. The 
CD4 count is a good immunological marker of disease progression. Thus 
>25% means that there is no immune suppression; 15–24% means moderate 
suppression and <15% means severe suppression (World Health 
Organisation, 2005). 
 
1.2.3 Initiation of anti-retrovirals 
The South African Government’s response to the epidemic is grounded in the 
HIV/AIDS strategic plan for the period 2000-2005. “An operational plan for 
Comprehensive Treatment and Care” (National Department of Health, 2003) 
was adopted in November 2003 to begin the roll out of an ARV programme. 
At the end of 2005 Gauteng had nearly 10 000 patients on ARVs. 
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In the United States the roll out of anti-retrovirals commenced in 1994 and 
since then, the incidence of opportunistic infections including pneumocystis 
jirovecii  pneumonia (PJP) has declined considerably (Kaplan et al, 2000).  
Prior to the introduction of anti-retrovirals in 2004 in South Africa, respiratory 
tract infections were found in over 90% of HIV infected African children at post 
mortem and accounted for 30-40% of paediatric inpatient admissions in HIV 
endemic regions with case fatality rates of between 15-28% (Zwi et al, 2000). 
This was confirmed in a study by Langston et al (2001). A prospective study 
conducted at a Durban hospital in 2000, established that 60% of the admitted 
children were HIV-1 infected (Pillay et al, 2001).  
The high prevalence of respiratory conditions (Zwi et al, 2000) may have been 
partly attributable to many children not on HAART or had an undiagnosed HIV 
infection. Decision-making about starting treatment is particularly important for 
children aged under 12 months as the probability of death in untreated HIV-
infected children is high: mortality rates of up to 40% by the age of one year 
have been reported (World Health Organisation, 2007).  
The prevalence of respiratory infections may be quite different since the 
introduction of HAART. However it may also be possible that studies may find 
similar results as respiratory conditions may remain prevalent due to poor 
adherence to the proper use of HAART. Poor adherence may be due to poor 
access to health care services, inadequate nutrition, unstable living 
conditions, or commonly discomfort with disclosure (Cowburn et al, 2004).  
 
1.2.4 The role of physiotherapy 
A study completed at Chris Hani Baragwanath Hospital in 2005 revealed that 
of the HIV infected adult patients suitable for physiotherapy only two percent 
were actually referred (Myezwa, 2007). This is alarming as physiotherapy has 
a role to play in the management of HIV infected patients particularly those 
with respiratory conditions (McClure, 1993; Wallis et al, 1999; Graham, 2007). 
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A study by Cowburn (2004) completed in Cape Town raised an issue that 
health care workers cannot adopt a deontological approach when treating 
patients infected with HIV due to “a high incidence of HIV infection and lack of 
access to HAART, coupled with resource constraints”. Jeena (2005) 
discusses that in developing countries a much more utilitarian view has to 
apply until such time that resources to practise at optimum levels become 
available. However the question to be raised should be whether these health 
care workers are using the resources that are available optimally. It was 
emphasized that data are urgently required to guide policy, resource 
allocation and ethical decision making in this setting. Research with regard to 
HIV and respiratory care is scant and is thus required in order to develop data 
upon which policies can be built. 
 
1.3 Purpose of study 
The purpose of the study is to understand the disease profile of hospitalised children 
with HIV/AIDS with regard to the presence of respiratory conditions with which they 
present, the indication for chest physiotherapy and their health status.  
 
1.4 Research question 
 
The study sought to explore the following question: 
What is the prevalence of respiratory conditions among paediatric patients infected 
with HIV/AIDS who are admitted to hospital? 
What is the indication for chest physiotherapy among these patients? 
What is the relationship between the burden of respiratory disease with certain 
influencing factors? 
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1.5 Aim 
 
To determine the burden of disease with regard to the prevalence of respiratory 
conditions among paediatric patients infected with HIV/AIDS and to establish the 
indication for chest physiotherapy. 
 
1.6 Objectives 
 
1. To establish the profile of  respiratory conditions presented by paediatric patients 
infected with HIV/AIDS admitted to medical wards with a respiratory condition.  
2. To establish the prevalence of paediatric patients infected with HIV/AIDS and 
presenting with a respiratory infection requiring chest physiotherapy  
3. To establish whether a relationship exists between the burden of respiratory 
disease and influencing factors including the use of antiretroviral drug 
combinations, length of drug use, CD4 counts and viral load. 
 
1.7 Significance of study 
 
With the prevalence of HIV/AIDS in our country, it is important that physiotherapists 
are informed about the condition and its clinical manifestations. This may assist 
physiotherapists working with these patients with their clinical decision making. An 
understanding of the medical and physiotherapy management may contribute to 
improved service delivery in our hospitals.    
 
The results of this study will help the appropriate allocation of physiotherapists based 
on the need for more physiotherapists and the establishment of protocols regarding 
improved holistic management of patients infected with HIV. 
 
HIV is a prominent infection in society and its health implications are seen in the 
paediatric wards daily. Despite its multi-system effect on the body, it particularly 
results in many respiratory infections. Effective understanding of the disease profile 
and management of patients with HIV relies on correct statistics and proper use of 
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resources. It is thus necessary to establish the health status of paediatric patients 
infected with HIV, the prevalence of respiratory infections presented and whether 
there is a indication for physiotherapy.  
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CHAPTER TWO 
Literature Review 
 
2.1 Introduction 
The first presentation of HIV-related lung disease is usually in infants or children 
younger than five years of age (Graham, 2005). Girls tend to be better protected 
against acute respiratory tract infections than boys, although the difference is not 
significant nor well understood (Kristensen et al, 2006). 
 
The distribution of respiratory disease relevant to HIV, indication of physiotherapy, 
anti-retroviral treatment, prevention of mother to child transmission and the burden of 
respiratory disease will be covered. 
 
The literature reviewed included published articles dated from 1994 to the present. 
Key words used included paediatric HIV/AIDS, opportunistic respiratory infections, 
anti-retroviral drugs, chest physiotherapy, burden of respiratory disease, CD4 counts 
and viral loads. Search engines explored included Pubmed, Pedro and article 
reference lists. 
 
2.2  Distribution of respiratory conditions 
 
The HIV/AIDS epidemic has directly impacted on the epidemiology and spectrum of 
childhood respiratory illness and the efficacy of therapeutic and preventative 
strategies (Zar, 2008). There is an escalation of pulmonary disease among the 
patients infected with HIV/AIDS, particularly in Sub-Saharan Africa.  
 
To an extent the incidence of acute infections has declined due to improved survival 
and management (Zar 2008), however the incidence of chronic infections has 
increased as the children infected with HIV/AIDS are living longer. This is directly 
influenced by the introduction of anti-retrovirals. Despite this Zar (2008) states that 
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respiratory disease still remains a major cause of morbidity and mortality amongst 
HIV-infected children. 
 
 
During the pre-HAART era, acute infections such as bacterial pneumonia, 
pneumocyctis jirovecii pneumonia (PJP) and disseminated mycobacterium avium 
complex were amongst the most frequent conditions diagnosed (Zar, 2008). This 
distribution is rapidly shifting towards the chronic spectrum with conditions such as 
lymphocytic interstitial pneumonia (LIP), immune reconstitution inflammatory 
syndrome (IRIS), bronchiectasis, malignancies, and interstitial pneumonitis receiving 
attention (Zar, 2008). 
 
Due to the nature of the disease and an increased susceptibility to infections mixed 
infections are common such as bacterial pneumonia or cytomegalovirus (CMV) with 
PJP, or bacterial pneumonia complicating viral pneumonia, PTB, or LIP (Graham, 
2003). This occurence contributes to the burden of disease, affects the health status 
and complicates the management process. With the introduction of anti-retrovirals 
and the incidence of mixed infections, the occurence of an immune reconstitution 
inflammatory syndrome has been reported (Zar, 2008), particularly associated with 
mycobacterial and cytomegalovirus infections.  
 
In developing countries such as South Africa it is of value to note the multi-factorial 
forces that impact on health. Economic disparity, with resultant widespread poverty, 
poor living conditions, and malnutrition occurring in children in developing countries, 
leads to poor respiratory health as reported by Zar et al (2003). This is illustrated in 
the statistics that 35–59% of HIV-infected African children die within the first two 
years of life.  
 
Respiratory disease in the HIV/AIDS infected population thus remains a burden on 
the health system and as physiotherapists it is important that this disease and all its 
clinical associations be understood. 
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2.2.1 Pneumocystis jirovecii pneumonia (PJP) 
Pneumocystis jirovecii formerly known as pneumocystis carinii  pneumonia 
(PCP) was the most common opportunistic infection in HIV-infected infants 
prior to widespread prenatal HIV screening, prophylaxis, and HAART (Zar, 
2008). It has now become clear that HIV-infected individuals who respond to 
HAART with immunological improvement have a substantially decreased risk 
of developing PJP (Beck et al, 2001).  
 
However, its presence still remains for several reasons. Patients may not be 
aware of a positive status until they have acquired PJP, some may not adhere 
to taking anti-retrovirals and in some cases anti-retrovirals are ineffective or 
HAART and PJP prophylaxis is not available (Beck et al, 2001). 
 
Pneumocystis is an atypical fungus, with a global distribution that usually first 
causes infection early in childhood (Graham, 2005). Clinical findings depicting 
the presence of PJP include significant tachypnoea and hypoxia, cyanosis 
(Jeena, 2005), mild intermittent fever, a dry cough and minimal auscultatory 
findings with bilateral diffuse alveolar infiltrates (Marais, Rabie et al, 2006) or 
hyperinflation (Graham, 2005) on chest xray. Radiological findings may 
progress to features compatible with the acute respiratory distress syndrome 
(Jeena, 2005). It usually presents as an acute severe pneumonia however 
chronic infection may manifest into a cystic disease or develop a 
pneumatocoele (Zar, 2008).  Lactate dehydrogenase (LDH) level is usually 
markedly elevated, although this is not specific. Diagnosis may also be made 
upon the discovery of immunofluorescent stained cysts in induced sputum or 
by polymerase chain reaction (PCR) testing (Graham, 2005). 
 
Currently PJP is less frequent than bacterial pneumonia as a cause of severe 
lung disease in HIV-infected children but is still the most important 
opportunistic infection in infants (Graham, 2005). It is regarded as a HIV 
defining illness and is categorised as a stage four disease according to the 
World Health Organisation’s clinical staging guidelines (2005). PJP is the 
indicator disease for AIDS in 20–40% of South African children. The 
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prevalence of PJP in children with ARI varies between 10% and 17% 
according to Jeena (2005). PJP remains an exceedingly common cause of 
death among HIV-infected infants in Africa, particularly in children under six 
months of age (bMarais et al, 2006). Graham (2003) reports that PJP presents 
with severe pneumonia, in infants between two to seven months old. However 
the incidence of PJP is much lower in HIV-infected children after one year of 
age and in countries where PJP prophylaxis is routine for infants born to HIV-
infected mothers (Graham, 2005). 
 
Response to therapy is relatively slow (bMarais et al, 2006). Management 
includes the use of a high-dose intravenous cotrimoxazole for a total duration 
of two to three weeks (bMarais et al, 2006), oxygen therapy and in the 
absence of CMV- steroids (Graham, 2005). Cotrimoxazole prophylaxis 
reduced mortality by 43% and the hospital admission rate by 23% in a cohort 
of children followed-up over 19 months (Chintu et al, 2004). Mechanical 
ventilation may be required and this poses a problem in a resource-
constrained environment. However, the benefit of oxygen therapy in reducing 
case fatality rates is likely to be lower for PJP than for bacterial pneumonia 
(Graham, 2005) - posing a dilemma for doctors in deciding which patient 
would benefit more.  
 
The current status of PJP prophylaxis in our country is commenced four to six 
weeks after birth (National Department of Health, 2010) or as soon as HIV is 
diagnosed but may be discontinued when the CD4 percentage is consistently 
> 20% for more than six months (National Department of Health, 2004). 
 
2.2.2 Bacterial pneumonia 
Bacterial pneumonia is common in all stages of HIV infection and at all ages 
(Jeena, 2005).  Streptococcus pneumonia is consistently the most common 
cause of bacterial pneumonia while haemophilus influenza pneumonia is also 
common in HIV-infected children, however its prevalence has been reduced in 
countries where routine immunisation with Hib vaccine has been introduced 
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(Mulholland, 2003; Jeena, 2005). Children with advanced HIV disease are at 
greater risk of recurrent infection and death (Graham, 2003). 
 
The Hib vaccine was introduced in 1990 and is currently administered at six, 
10 and 14 weeks of age (KZN Department of Health). The effectiveness of the 
vaccine is significantly reduced in HIV-infected compared with uninfected 
children (Madhi et al,  2002). The first pneumococcal vaccine was introduced 
in South Africa in April 2009 in an effort to reduce staphylococcal pneumonia 
infections (Madhi, 2008). 
 
Staphylococcus aureus, particularly methicillan resistant staphyloccal aureus 
(MRSA) strains have become common in children infected with HIV/AIDS 
(Graham, 2003; Zar, 2008). Staphylococcal pneumonia may be complicated 
by the development of an empyema, pneumatocoele or lung abscess (Zar, 
2008). Severe, destructive, persistent or recurrent bacterial pneumonia may 
lead to chronic lung disease such as bronchiectasis (Zar, 2008). 
 
The definition of pneumonia has been debated, however the ‘‘gold standard’’ 
investigation to define pneumonia is the chest radiograph (Mulholland, 2003). 
Unfortunately there has been little agreement between radiologists on the 
interpretation of what constitutes significant consolidation on a paediatric 
chest radiograph and this leads to exclusion of many pneumonia events that 
do not produce sufficient radiological changes (Mulholland, 2003). 
 
Major questions have remained unanswered, particularly in relation to the 
mortality burden of pneumonia (Mulholland, 2003).  Thus studies are required 
to understand the patterns of pneumonia and its mortality within and between 
communities. 
 
2.2.3 Viral pneumonia 
Viral pneumonia is less common than bacterial pneumonia however the 
persistence of a viral infection or chronic sequelae of an acute infection may 
lead to chronic lung disease (Zar, 2008).  
Burden of Respiratory Disease in Paediatric Patients infected with HIV/AIDS 
N. da Cunha 
 
13    | P a g e  
 
 
Other respiratory viruses such as respiratory syncytial virus (RSV), measles, 
influenza, parainfluenza and adenovirus are commonly seen in HIV-infected 
children with pneumonia (Jeena, 2005). Mulholland (2003) recognises that 
respiratory syncytial virus is the main viral cause of pneumonia. RSV is not 
limited by season in HIV infected children (bMadhi et al, 2000). The absolute 
burden of hospitalization for viral associated pneumonia is two to eight-fold 
greater in HIV-infected children (Zar, 2008). 
 
Measles pneumonia is categorised as a viral pneumonia. It may present in 
children with advanced immunosuppression without the typical 
mucocutaneous features, making diagnosis difficult (Graham, 2005). In 
children presenting with measles, the administration of vitamin A significantly 
reduces the likelihood of severe pneumonia and death (Graham, 2005). There 
are effective programmes that immunise around 80% of infants against 
measles at nine months of age and the provision of vitamin A to infants at six 
months of age has reduced both the incidence of measles and measles-
related mortality (Graham, 2005). 
 
Adenovirus and herpes viruses have been described as causes of severe and 
fatal pneumonia in HIV-infected children, however autopsy studies generally 
find them to be uncommon (Graham, 2005). 
 
2.2.4 Tuberculosis 
Tuberculosis poses a large burden to the Sub-Saharan population and it is 
fuelled by the immune compromise that results from HIV infection (bMarais et 
al, 2006). HIV-infected children have an increased risk of developing 
pulmonary TB and complicated or disseminated disease compared to 
uninfected children (Zar, 2008).  HIV infected children are not only more 
vulnerable to progress to disease, but are also more likely to be exposed to 
TB and become infected or re-infected (bMarais et al, 2006). 
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A recent report by aMarais et al (2006) from Cape Town indicated that children 
under 13 years of age contributed 13.7% of the total TB disease burden, with 
a calculated TB incidence rate of more than 400/100 000 per year. TB can 
present at any age, even in neonates. An increased incidence of congenital 
TB has been associated with maternal HIV-infection (bMarais et al, 2006). In a 
prospective study from Côte d’Ivoire, the risk of TB was four times higher in 
children with CD4 percentage below 15% than in those with CD4 % above 
15% (bMarais et al, 2006). 
 
Clinical findings according to the WHO criteria for diagnosis of TB is a cough 
of more than two weeks, failure to thrive and weight loss (bMarais et al, 2006), 
however these symptoms are usually already present in the HIV-infected 
child. Less specific signs include coughing, wheezing, tiredness and or failure 
to thrive. 
 
One of the diagnostic tools such as the tuberculin skin test (TST) is of re-
duced value in HIV-infected children (Zar, 2008), as a compromised immune 
system due to severe malnutrition, low CD4 counts and progressive HIV 
disease are associated with false negative TST results (bMarais et al, 2006). 
Induced sputum and gastric aspirates may assist in yielding a positive culture, 
however a study reports that the yield in one induced sputum is equal to three 
gastric aspirates (Zar et al, 2005).  Induced sputum using hypertonic saline 
should therefore be the primary diagnostic procedure in a child with suspected 
pulmonary TB (Zar, 2008). Chest radiographs are done to assist in the 
diagnosis but are not confirmatory, rather assistive towards a diagnosis 
(Marais et al, 2007). Statistics may be under or over evaluated due to the 
typical miliary picture of disseminated TB which may be mimicked by the 
reticulonodular pattern of lymphoid interstitial pneumonitis (LIP) (bMarais et al, 
2006). 
 
Prevention of TB in this country has been of priority and widespread 
education has been conducted. BCG or Bacillus Calmette Gurin vaccination 
against TB is given to all infants at birth. In HIV-infected children, there is an 
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increased risk of developing BCG associated complications, such as local or 
disseminated BCG disease (bMarais et al, 2006). Disseminated BCG disease 
has a poor prognosis with a case fatality rate of approximately 50% (Zar, 
2008). Despite this, the current recommendation is to vaccinate all children 
irrespective of HIV-exposure, but to remain vigilant of BCG-associated 
complications as the benefits of BCG vaccination outweigh the risks (World 
Health Organisation, 2006). 
 
The treatment regimen for TB consists of isoniazid (INH), rifampicin and 
pyrazinamide (PZA), given as fixed dose combination therapy, during two 
month intensive phase followed by INH and RMP during the four month con-
tinuation phase (bMarais et al, 2006). Treatment should be closely observed to 
promote adherence and reduce the chances of treatment relapse or failure. 
Directly observed therapy (DOT) should be used as poor adherence 
manifests multi-drug resistant forms that pose a grave risk, particularly to 
vulnerable HIV-infected children (Zar, 2008). 
 
Co-infection with tuberculosis and HIV results in more rapid deterioration of 
immune dysfunction, viral replication, and HIV progression and more 
frequently other severe infections (Zar, 2008). Due to the strong association 
between TB and HIV, it is often required that treatment be initiated 
simultaneously. Immune reconstitution inflammatory syndrome (IRIS) may 
occur as the side-effects of TB treatment are exacerbated by the anti-
retrovirals (bMarais et al, 2006). IRIS usually manifests within two to six 
months after the initiation of HAART and subsides spontaneously, although 
severe cases may require treatment with corticosteroids. 
 
2.2.5 Mycobacterium avium complex 
MAC is a non-tuberculous mycobacterium (NTM) of which the risk of infection 
is associated with CD4 counts less than 50 cells/mL in adults, but this 
threshold is less well established in young children (Zar, 2008). In a study 
done by Langston et al (2001), it was found that MAC is the underlying or 
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contributing cause of death in 42% of all HIV-related mortalities. The use of 
HAART dramatically reduces the incidence of NTM disease in children. 
Primary prophylaxis for children is given according to the age and CD4 counts 
and secondary prophylaxis to children with a history of NTM to prevent 
reoccurrence (Zar, 2008). Respiratory symptoms may occur but are 
uncommon, the usual presentation being weight loss, fever, abdominal pain 
and diarrhoea (Graham, 2005). 
 
2.2.6 Lymphoid interstitial pneumonitis 
Lymphoid interstitial pneumonitis (LIP) is a common cause of chronic 
respiratory disease in HIV-infected African children (Graham, 2003). LIP 
occurs in approximately 20–30% of HIV-infected children, usually presents 
after two years of age, and is associated with pneumonia and bronchiectasis 
(Graham, 2003). Swigris et al (2002) confirms that LIP occurs most often in 
the second or third year of life. Lynch et al (2001) and Becciolini et al (2001) 
both support the statistics in stating that 30-40% of patients infected 
perinatally will develop LIP.  
 
LIP is not associated with as poor an outcome as PJP. Rather, children with 
LIP can survive for years with a clinical course characterised by intermittent 
episodes of superimposed bacterial pneumonia and eventual bronchiectasis 
or cor pulmonale.  (Graham, 2005 ; Rabie et al, 2007). 
 
LIP presents as a slowly progressing interstitial disease with mild hypoxaemia 
and is usually characterized by a cough, generalised lymphadenopathy,  
digital clubbing (Lynch et al, 2001), respiratory distress, failure to thrive 
(Swigris et al, 2002), hepatosplenomegaly and parotid enlargement (Rabie et 
al, 2007). 
 
Lymphoid interstitial pneumonitis presents with reticular, nodular or 
recticulonodular parenchymal changes (Jeena, 2005). Chest radiographs 
often show a diffuse reticulonodular pattern, more pronounced centrally which 
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may be difficult to distinguish from pulmonary or miliary TB  (Zar, 2008). If 
there is clinical suspicion of TB despite negative skin test and sputum culture 
results, the child should be treated with anti-tuberculous therapy for six 
months before the diagnosis of LIP is made (Simmank et al, 2001).  
 
A lung biopsy is suggested as a means of correctly diagnosing LIP (Oldham 
et al, 1989). In some lung biopsy specimens Epstein-Barr virus has been 
found (Swigris et al, 2002). In view of the fact that LIP is often misdiagnosed 
as TB (Graham, 2003), the accuracy of LIP statistics should be questioned. 
 
2.2.7 Bronchiectasis 
Bronchiectasis is a irreversible dilatation of the airways that disrupts normal 
airway functioning and usually results from severe and recurrent infections 
(Rabie et al, 2007) such as recurrent bacterial pneumonia, LIP and PTB 
(Graham, 2005) leading to the damage of the bronchial wall beyond repair 
(Sheikh et al, 1997).  It is a common problem and occurs in up to 16% of 
children (Rabie et al, 2007). This is supported by Sheikh et al (1997), where 
15,8% of patients with a mean age seven point five years developed 
bronchiectasis.  
 
Classically the production of copious amounts of purulent sputum is 
described, but young children frequently swallow their sputum, making this a 
less obvious symptom (Rabie et al, 2007).  Coughing is often worse at night, 
while other classical signs include clubbing, halitosis and coarse crackles 
(Graham, 2005; Zar, 2008). 
Chest radiographs show focal abnormalities with bronchial dilatation (Graham, 
2005). These abnormalities are often displayed by a honeycomb appearance 
with small cysts, persistent areas of opacification or widespread lung 
destruction, usually with fibrosis and volume loss (Rabie et al, 2007). 
Treatment includes broad-spectrum antibiotics and chest physiotherapy 
(Rabie et al, 2007; Graham, 2005). 
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2.2.8 CMV pneumonitis 
Cytomegalovirus infection is common in HIV-infected children, but its role in 
causing disease is difficult to assess (Graham, 2005). An autopsy study of 
Zambian infants and children who died of pneumonia reported CMV as the 
third commonest finding in HIV-infected infants, after pyogenic pneumonia 
and PJP (Graham, 2005). CMV is common in HIV-infected infants with 
pneumonia, often in association with PJP (Graham, 2003).  
 
Co-infection with CMV and HIV results in more rapid progression of HIV 
disease (Zar, 2008). The use of HAART has resulted in a substantial 
decrease in the incidence of CMV infection (Gona et al, 2006). 
 
Radiographic abnormalities due to CMV are typically diffuse, interstitial 
infiltrates similar to PJP (Graham, 2005). Treatment with gancyclovir is 
advocated for patients with CMV retinitis, gastrointestinal involvement and 
severe lung disease (Jeena, 2005). 
 
2.3 Indication for physiotherapy 
A group of expert physiotherapists lead a movement towards leaving the term “chest 
physiotherapy” behind and to replace it by “airway clearance techniques” as a group 
name for all of the techniques and devices that have been developed (De Boeck et 
al, 2008). 
 
Examples of such techniques include manual chest compression during expiration, 
autogenic drainage, active cycle of breathing, manual cough assist techniques, 
devices directed at huff coughing, high-frequency chest wall compression, 
intrapulmonary percussive ventilation, oscillatory devices such as flutter, and positive 
expiratory pressure (PEP) mask and their derivatives (De Boeck et al, 2008). 
 
De Boeck et al (2008) reviewed literature that shows that airway clearance 
techniques are not useful on previously healthy children and believe that children 
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have the ability to cope and heal independently. However,  should patients be 
selected according to their ability to cope with treatment and their need to improve 
gaseous exchange and reduce fatigue of removing secretions then it may be 
beneficial. 
 
Positioning to optimize V/Q matching, ease work of breathing, relaxation techniques 
and breathing control are aspects of treatment that physiotherapists may provide 
patients presenting with PJP (McClure, 1993). Confirmation of PJP and TB may be 
assisted via induced sputum (Graham, 2007). Positive expiratory pressure (PEP) 
has been shown to be useful in improving ventilation and reducing the volume of 
trapped gas while collateral ventilation is recruited to expand airways and mobilise 
secretions (Lannefors et al, 2004). 
 
Lymphocytic interstitial pneumonitis (LIP) presents clinically with a productive cough, 
poor posture and reduced exercise tolerance all of which physiotherapists can 
manage with manual chest techniques, posture analysis and exercise prescription.  
 
During the acute stages of bronchiectasis, patients can be treated with chest 
techniques, positioning and exercise endurance and then with postural drainage and 
effective coughing exercises during the chronic phase (Sheikh et al, 1997). Airway 
clearance therapy is traditionally considered the cornerstone of therapy for the 
prevention and treatment of cystic fibrosis lung disease or other causes of 
bronchiectasis (Schechter, 2007) but efficacy is somewhat an article of faith, backed 
by voluminous clinical experience and moderately convincing but by no means 
definitive evidence. 
 
Patients with diseases known to cause clearance abnormalities can have sputum 
clearance with some techniques, such as positive expiratory pressure, autogenic 
drainage, and active cycle of breathing techniques (Wallis et al, 1999). 
Bronchodilators and manual chest therapy may also be helpful (Graham, 2005). 
In ventilated children, chest physiotherapy with saline lavage and stimulated cough 
was successful in improving lung expansion in 84% of patients (Galvis et al, 1994). 
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This has been confirmed by Peroni and Boner (2000). The prescription of physical 
exercise proves helpful in patients with chronic lung disease as it improves airway 
clearance and breathing volumes (Lannefors et al, 2004). 
Indications or contraindications for or against chest physiotherapy should never be 
formulated on the basis of diagnostic entities but should rather stem from a detailed 
analysis of the prevailing individual pathophysiology (Oberwaldner, 2000). 
 
2.4 Anti-retrovirals 
Since the introduction of anti-retrovirals in South Africa in 2004, there has been a 
large upscale in treatment programmes. The South African anti-retroviral treatment 
programme reached 81% of children in need of anti-retrovirals in 2009 (Republic of 
South Africa, 2010). In a sample of 270 patients in Ivory Coast, fifty-seven percent 
were on anti-retrovirals (Kouakoussui et al, 2004). 
 
According to the National Antiretroviral Treatment Guideline (2004) patients are 
eligible for anti-retroviral therapy when they present with recurrent hospitalisations 
(i.e. more than two admissions per year) for a HIV-related disease, or a prolonged 
hospitalisation regarded as more than four weeks. Treatment may also commence 
should the child present with a modified WHO stage two or three disease, a CD4 
percentage < 20% in a child under 18 months old or a CD4 percentage < 15% in a 
child over 18 months old. This has been recognised in an article by Rabie et al 
(2006). According to the National Department of Health South Africa (2010), the 
current guidelines state, anti-retroviral treatment may begin immediately in children 
under one, when the CD4 % is under 25 in children aged one to five years, or the 
CD4 count is under 350 in children above five years. 
 
The normal CD4 cell count varies with age, starting high and then declining slowly to 
reach adult values around 5 years of age, however, the number of CD4 cells 
expressed as a percentage of the total lymphocyte count remains fairly stable (Rabie 
et al, 2006). Hence CD4 % is a stronger predictor of immune status. 
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In both adults and children starting anti-retrovirals, mortality was highest in the first 
six months of therapy, however after two years of use, 85.7% of children had 
achieved a CD4 greater than 20% of lymphocytes (Boulle et al, 2008).  
 
Zolopa et al (2009) randomised a sample of 282 subjects into early and late initiation 
of ARV groups. The ‘early group’ regarded as receiving ARV’s during the presence 
of an opportunistic infection instead of after, spent less time with CD4 counts below 
50 cells/ml and therefore the ‘‘window of vulnerability’’ to additional AIDS-related 
complications was shortened. A European Collaborative Study (2006) suggests that 
there is a benefit of initiating ARV’s before the age of five months.  
 
Another study demonstrated that after highly active anti-retroviral treatment (HAART) 
the incidence of respiratory infections decreased dramatically compared to before 
HAART. It was, however, only statistically significant in children over five years old 
and those severely immunocompromised regarded as a CD4 percentage under five 
percent (Kouakoussui et al, 2004). 
 
After one year of HAART a study demonstrated that 69.7% of children had a viral 
load < 400 copies/ml thus the comparative analysis showed significant 
improvements in growth, immunological status and virological control (Eley et al, 
2006). A South African study (CHER) demonstrated that the early diagnosis of HIV 
and early antiretroviral therapy reduced early infant mortality by 76% and HIV 
progression by 75% compared to children with a deferred treatment program (Violari 
et al, 2008).  
 
For children infected with HIV/AIDS, the timing of HAART after initiation of TB 
therapy depends on the clinical and immunological severity of disease. In those with 
severe clinical illness or advanced HIV, HAART should be started two to eight weeks 
after TB therapy to minimize the risk of immune reconstitution syndrome, optimize 
adherence, and differentiate potential side effects due to TB or antiretroviral drugs 
(Zar, 2008). Immune reconstitution syndrome is a paradoxical clinical deterioration 
after starting HAART, due to the improving immune system interacting with 
organisms that have colonised the body during the early stages of HIV infection 
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(National Antiretroviral Treatment Guideline, 2004). For instance, rifampicin is a TB 
drug that induces hepatic cytochrome P450 enzymes which may reduce levels of 
antiretroviral agents (Zar, 2008). 
 
To improve the survival of young, HIV-infected children in Africa, early diagnosis 
must be coupled with comprehensive monitoring and care, including the timely 
introduction of HAART (Eley et al, 2007). HIV-infected children who adhere to a 
regimen of HAART are likely to enjoy suppression of HIV replication, and 
preservation or improvement in immunological function, with a reduced incidence of 
opportunistic events and mortality (Beck et al, 2001). 
 
 
2.5 Prevention of mother to child transmission 
Of the approximately 800,000 public sector births in South Africa in 2006, about 
580,880 pregnant women were offered PMTCT services (Department of Health, 
2007). In 2002 there were almost 339 000 orphans in South Africa, as a direct result 
of HIV/AIDS and the ASSA 2000 model predicted that in 2010 this number would 
increase to 1,5 million (Doherty et al, 2002). 
Maternal death early in childhood is very common in the African context (Graham, 
2003) and major risk factor for poor survival in HIV-exposed infants (Graham, 2005) 
as morbidity and mortality are affected by poor adherance to medication and 
nutritional care. Poor compliance may be an additional factor to incidence of acute 
respiratory infections, as social disruption due to death of a parent is common for 
HIV-infected children (Graham et al, 2001). 
 
Breastfeeding remains a topic of debate in transmission of HIV/AIDS however 
findings in a Soweto based study tends to support suggestions that breastfeeding 
may confer protection against the severity rather than the incidence of acute 
respiratory infections. Breastfeeding showed a tendency towards protection against 
more severe acute respiratory infections (Kristensen et al, 2006). A study based in 
Malawi, demonstrated that breastfeeding by women infected with HIV was not 
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associated with mortality or morbidity; rather it was associated with highly significant 
reductions in mortality among their children (Taha et al, 2006). 
 
A Cochrane review (Volmink et al, 2009) confirms that antiretroviral treatment 
administered in the perinatal period compared with placebo lowers the risk of 
mother-to-child transmission of HIV. The length of treatment appears to influence 
transmission rates with a longer antenatal component being the most important 
(Volmink et al, 2009).  
 
Current guidelines recommend that all HIV-exposed infants should receive single 
dose Neviripine (NVP) post-delivery and the low-dose NVP for six weeks. At six 
weeks if the mother is on lifelong anti-retrovirals or the baby is not receiving any 
breast milk, then NVP may be stopped otherwise continue or as long as infant is 
receiving any breast milk (National Department of Health, 2010). 
 
2.6 Burden of respiratory disease 
From a global perspective, children from sub-Saharan Africa carry by far the 
heaviest burden of HIV-related respiratory disease (Graham et al, 2001). Acute 
respiratory infections account for 20% of the global under five years mortality in 
childhood (Jeena, 2005). Another study mentioned mortality rates of 26% by one 
year and of 62% by five years (Graham et al, 2001). 
 
The prevalence of HIV infection is less than five percent among children aged under 
five years, however children this age accounted for 45% of those hospitalized and 
84.7% of those who died because of severe lower respiratory tract infections (Madhi 
et al, 2000). Children with HIV who survive longer are less likely to die of pulmonary 
disease or infection and more likely to die of cardiac causes or with wasting 
syndrome  (Langston et al, 2001). 
 
Immune status and respiratory disease may influence the burden of disease among 
infected children.  A CD4 cell count of under 50mm3  was a significant predicator of 
mortality in a group of 309 adult patients in Durban (Ojikutu et al, 2008) yet in a study 
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of 151 children at the same clinic the CD4 count was not  a predictor (Reddi et al, 
2007). Autopsy studies show, as in Zambia, that among respiratory causes of death 
the three major causes are acute pyogenic pneumonia, pneumocystis carinii and 
cytomegalovirus in HIV-1 infected children (Kouakoussui et al, 2004). Pneumocystis 
jirovecii pneumonia (PJP) and bacterial pneumonia have become a major cause of 
hospitalization and death in HIV-infected children according to Zar et al (2003). A 
longer duration of illness and greater case fatality rate in both well-nourished and 
malnourished HIV-1–infected children may be related to PJP (bMadhi et al, 2000). 
The admission rate for acute lower respiratory tract infections in children with LIP 
was approximately twice that of children without (Simmank et al, 2001). In a 2000 
study by bMadhi et al, the overall case fatality rate was 13.1%. 
 
2.7 Conclusion 
 
The HIV/AIDS epidemic has had a large impact on Sub-Saharan African children, 
which subsequently affects the health system. Respiratory disease is a common 
cause of morbidity associated with HIV/AIDS. Since the introduction of anti-
retrovirals in 2004 in South Africa, the impact of HIV/AIDS on respiratory disease 
needs to be re-evaluated with further studies. Identifying the prevalence and variety 
of respiratory conditions and identifying its relationship with factors such as age, 
immune status and the indication for physiotherapy may provide evidence on the 
burden of respiratory disease among children under the age of seven, most of whom 
were born within the post-HAART era. 
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CHAPTER THREE 
Methodology 
 
In this chapter, the methodology used in this cross sectional study will be discussed. 
The location of the study, ethical clearance, sample collection, study population, 
assessment tools, procedure and statistical analysis have been included. 
 
3.1 Location 
This study was conducted at Steve Biko Academic Hospital (Pretoria) in all 
paediatric wards and at Chris Hani Baragwanath Hospital (Johannesburg) in 
three paediatric wards. All the paediatric wards at Steve Biko Academic 
Hospital admit medical patients whereas at Chris Hani Baragwanath Hospital 
there are three assigned wards that admit medical patients. Both hospitals are 
large tertiary, academic hospitals situated in urban Gauteng, South Africa. 
 
3.2 Ethical clearance 
Ethical clearance was obtained from the Human Research Medical Ethics 
Committee at the University of the Witwatersrand – protocol number M080955 
(Appendix I) and from the Faculty of Health Sciences Research Ethics 
Committee at the University of Pretoria- protocol number 214/2008  
(Appendix II). 
 
Permission was granted from the CEO at Steve Biko Academic Hospital 
(2008/10/13) (Appendix III) and the Medical Superintendent at Chris Hani 
Baragwanath Hospital (2009/08/06) (Appendix IV) as well as both Heads of 
Department of Paediatrics to conduct the study at these hospitals . 
 
3.3 Sample collection 
 
One hundred and twenty-five consecutive patients (63 from Steve Biko 
Academic and 62 from Chris Hani Baragwanath Hospital) infected with 
HIV/AIDS admitted to the hospitals with a respiratory condition were recruited 
once informed consent was obtained from the caregivers. 
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3.3.1 Inclusion criteria 
 Patients under seven years of age admitted to the paediatric 
medical wards with a respiratory condition and infected with 
HIV/AIDS 
 
3.3.2 Exclusion criteria 
 Patients who are not infected with HIV/AIDS 
 Patients whose caregivers did not provide informed consent 
 
3.4 Study population 
 
Steve Biko Academic and Chris Hani Baragwanath are both tertiary hospitals 
and hence admit patients according to similar protocols. All patients are 
managed by paediatric pulmonology consultants, registrars and rotating intern 
and student doctors. One hundred and twenty five patients were assessed 
and the children’s files were reviewed for data which were analysed to meet 
the research objectives. 
 
3.5 Assessment tool 
 
A data collection form (Appendix V) was completed by the researcher and 
used to note information extracted from the patients files. The form identified: 
 
 Diagnosis of the respiratory condition(s) 
 Whether physiotherapy intervention was necessary 
 Reason for physiotherapy intervention according to a check list 
(Appendix VIII) 
 Whether the patient was receiving or not receiving antiretroviral therapy, 
which combination was administered and the length of drug use 
 The patients’ history of ARV drug combination use and whether the 
mother was on ARV’s  
 The CD4 count and viral load 
 Age and gender of patient 
 Length of hospital stay  
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3.6 Procedure 
 
During the research period, a list of new patients was created upon  
admission. The files of the patients were screened for subject recruitment 
following inclusion and exclusion criteria.  
The caregiver was then approached and the information sheet (Appendix VI) 
read and discussed. The meeting with the caregiver was completed in a 
private room so that the caregiver did not feel compelled to provide consent in 
the presence of other caregivers in the ward. A translator was utilised in the 
event that the caregiver could not understand English or if the caregiver was 
not able to read the information sheet. The third person would therefore sign 
the verbal consent form as a witness. In the event of the caregivers’ absence, 
telephone calls were made and consent was requested. The caregivers were 
requested to sign consent (Appendix VII) when visiting the hospital. In the 
event of after-hours visits the sister in charge of the ward was asked to obtain 
consent from the caregivers.  
 
Once consent was achieved, the information in the file was read to complete 
the data collection form and an objective respiratory assessment was 
completed to evaluate whether physiotherapy was necessary. This was done 
by following guidelines on a tick list (Appendix VIII).  A percentage of patients 
were also evaluated objectively by a research assistant who was another 
member of staff. The research assistant was blinded to the researcher’s 
findings in order to serve as an inter-rater reliability test. Physiotherapy 
treatment was commenced on the day of evaluation if it was deemed 
necessary. Treatment was either provided by the researcher, a physiotherapy 
student under the researcher’s supervision or by another qualified 
physiotherapist. The data collection form was completed at different intervals 
– two days post admission, five to seven days post admission and repeatedly 
five to seven days later until discharge and then at discharge.  
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During the data collection procedure, all respiratory conditions presented by 
the patients enrolled in the study were documented. The conditions were 
reviewed and it was documented whether the respiratory condition presented 
was treatable by chest physiotherapy according to literature, findings of the 
evaluation and guidelines set by the researcher. Data collection sheets were 
stored in a safe in the physiotherapy department until discharge of the patient 
after which they were kept in a safe place. 
The relationship between the burden of respiratory disease and influencing 
factors such as the use of anti-retrovirals, ARV combinations and length of 
use, the CD4 count and viral load according to laboratory results was 
analysed. The age, gender and length of hospital stay of each patient was 
recorded for demographic analysis. The results were statistically reviewed 
once the findings were collated. 
 
3.7 Statistical analysis 
 
The following objectives would be analysed during a statistical appraisal of 
this study: 
 proportion of paediatric patients with HIV/AIDS admitted to the medical 
wards with respiratory conditions requiring physiotherapy 
 distribution of respiratory conditions in paediatric patients with HIV/AIDS 
 proportion of patients on ARV’s 
 among the patients using ARV’s find the length of use 
 determine the relationship between the burden of respiratory disease 
(categories: one condition only, between two to three conditions and four 
or more conditions) and the influencing factors (ARV use, CD4 count, viral 
load, age, gender)  
 relationship between length of hospital stay and respiratory disease 
category with the influencing factors 
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 Sample size was determined with reference to the proportion of patients 
with respiratory conditions requiring physiotherapy. It was conservatively 
assumed that the expected proportion of patients that required 
physiotherapy would be 50 %, then a sample of at least 97 patients would 
estimate the proportion to an accuracy of at least 10% with a 95% 
confidence interval. It was then assumed that 80% of all patients with 
respiratory disease would require physiotherapy then at least 125 patients 
would need to be screened. 
 
The data of 125 patients was thus reviewed and analysed as follows: 
 The proportion of subjects that require physiotherapy along with a 95% 
confidence interval and similarly for the proportion of those patients on 
anti-retrovirals was found.   
 The relationship between the respiratory categories and influencing factors 
was investigated using logistic or polytomous logistic regression. 
 The relationship between length of stay and the influencing factors 
employed time to event (survival) analysis. Interpretation was performed at 
a 0.05 level of significance. 
 
The results of this study will be presented in chapter four. 
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CHAPTER FOUR 
Results 
 
In this chapter, the results of the study will be presented. The results are presented 
under the following topics: demographic information, distribution of respiratory 
conditions in paediatric patients with HIV, proportion of patients with respiratory 
conditions requiring physiotherapy, status of anti-retroviral use, patient immune 
status, relationship between the burden of respiratory disease and the influencing 
factors and the relationship between the burden of respiratory disease and the length 
of hospital stay. 
 
4.1 Demographic information 
 
 4.1.1 Age distribution 
 
The age distribution of the sample is presented in table 4.1. 
 
Table 4.1 Age distribution (n=125) 
 
 
Mean 
 
SD* 
 
Median 
 
IQR** 
Age in months 20.55 23.64 
 
11 
 
 
4 - 29 
 
 
*  SD  - standard deviation 
**  IQR – inter-quartile range 
 
The average age of all the children recruited who were all under seven 
years (84 months) was 20.55 months (SD=23.64). 
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 4.1.2 Gender distribution 
 
The gender distribution of the sample is presented in Figure 4.1. 
 
 
  Figure 4.1 Gender distribution (n=125) 
 
 The total number of patients n=125 was represented by slightly more 
boys (55.2%) than girls (44.8%). 
 
 4.1.3 Length of hospital stay distribution 
 
  The length of hospital stay of the sample is presented in table 4.2. 
 
 Table 4.2 Length of stay distribution (n=125) 
 
 
Mean 
 
SD* 
 
Median 
 
IQR** 
Hospital stay in days 18.76 19.19 
 
13 
 
 
8 - 23 
 
       
      *  SD  - standard deviation 
                                    **  IQR – inter-quartile range 
 
The average length of admission to hospital was 18.76 days 
(SD=19.19), approximately 2 ½ weeks. The median was approximately 
2 weeks (13 days). 
55.2%
44.8%
Gender Distribution
Boys
Girls
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 4.1.4 Outcome post admission distribution 
 
The outcome of the sample (n=125) after admission is presented in 
figure 4.2 
 
                                     Figure 4.2 Outcome post admission distribution 
 
The majority (80%) of the patients were discharged home, followed by 
10.4% transfer to another medical facility. Just less than ten percent 
(9.6%) of patients died in hospital. 
 
4.2  Distribution of respiratory conditions in paediatric patients      
with HIV 
 
4.2.1 Respiratory disease distribution 
 
The distribution of respiratory conditions was collated and categorised 
into eight groups. This is shown in figure 4.3. 
‘Bacterial pneumonia’ included all forms of bronchopneumonia, 
pneumonia, community and hospital acquired. ‘Viral pneumonia’ 
included bronchiolitis and all types of influenza. The ‘Other’ group 
included interstitial lung disease, emphyema, pleural effusion, 
laryngomalacia, bronchopulmonary dysplasia, mycobacterium avium 
complex (MAC), swine flu (H1N1) and lung fibrosis.  
9.6%
80%
Outcome post admission
Deceased
Discharged home
Transferred to 
another facility
10.4% 
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Figure 4.3 Distribution of respiratory conditions (n=239 conditions) 
 
The distribution of disease category expressed as a percentage of the 
total patients presenting with each is demonstrated in figure 4.4.  
 
 Figure 4.4 Percentage of patients presenting with each disease category 
83
60
29
23
14 14 10 6
Distribution of Respiratory Conditions
Number of 
conditions 
presented in 125 
patients
Bacterial Pneumonia
Tuberculosis
Pneumocystis Jirovecii …
CMV Pneumonitis
Bronchiectasis
Other
Viral Pneumonia
Lymphoid Interstitial …
66.4
48
23.2
18.4
11.2
11.2
8
4.8
Distribution of patients presenting with each disease category
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presenting with each disease 
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Bacterial pneumonia was the most commonly diagnosed respiratory 
condition (66.4%), followed by tuberculosis (48%) and pneumocystis 
jirovecii pneumonia (23.2%). Lymphoid interstitial pneumonitis was the 
least frequently diagnosed with only a 4.8 % presentation. 
 
4.2.2 Burden of disease  
Patients presented with one to four respiratory conditions as depicted 
in figure 4.5. 
 
   Figure 4.5 Distribution of the number of conditions presented 
 
These were then categorised as a ‘Low burden’ (only one condition) or 
a ‘High Burden’ (more than one condition) as shown in figure 4.6. 
 
 
31.20%
50.40%
16%
2.40%
1 2 3 4
Number of conditions presented
# Conditions
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Figure 4.6 Low versus High burden of disease 
 
Two thirds (68.8%) of all the patients can thus be classified as having a 
high burden of respiratory disease. 
4.3 Proportion of patients with respiratory conditions requiring 
physiotherapy 
 
The proportion of patients requiring physiotherapy is shown in table 4.3.  
Table 4.3 Indication for physiotherapy 
 
 
Mean 
 
SD 
 
Median 
 
IQR 
Maximum # days requiring physiotherapy 14.23 11.94 11 7 - 17 
Minimum # days requiring physiotherapy 11.11 11.98 7.5 4 – 12.75 
Average # days requiring physiotherapy 13 13.34 9.5 5 - 15 
    
   *  SD  - standard deviation 
  **  IQR – inter-quartile range 
 
Physiotherapy was indicated in 96 % of all the patients (n=125), therefore only 
five patients did not require physiotherapy at all. For the 120 patients who did 
31.2%
68.8%
Burden of disease
Low
High
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require physiotherapy the average indication for treatment was 13 days 
(SD=13.34). 
 
 
4.4  Status of anti-retroviral use 
 
4.4.1  Proportion of patients taking anti-retrovirals 
The proportion of children taking anti-retrovirals is demonstrated in 
figure 4.7.  
 
   Figure 4.7 Proportion of patients taking anti-retrovirals 
 
The number of children taking anti-retroviral medication was 51 
(40.8%), while the number of those children not on anti-retroviral 
medication was 74 (59.1%). 
Figure 4.8 demonstrates the breakdown of the status of anti-retroviral 
use. 
40.8%
59.1%
Proportion of patients taking anti-retrovirals
Taking Arvs
Not taking Arvs
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Figure 4.8 Breakdown of reasons for the status of ARV use 
 
The distribution of patients receiving anti-retrovirals was divided into 
those already taking the medication prior to admission (28.8% of all 
patients n=125) and those starting the medication during admission 
(12%). The patients not taking medication was either due to awaiting 
Arv initiation (50.4%) or because the child was receiving TB medication 
(8.8%). 
 
4.4.2  Average length of anti-retroviral use 
Table 4.4 depicts the average length of anti-retroviral drug use (n=36) 
of the children already taking anti-retrovirals prior to admission. 
 
Table 4.4 Average length of anti-retroviral drug use (n=36) 
 
 
 
Mean 
 
SD 
 
Median 
 
IQR 
Length of anti-retroviral use in 
months 9.81 11.61 
 
4.50 
 
 
1– 15.25 
 
     *  SD  - standard deviation 
     **  IQR – inter-quartile range 
 
Patient Arv Status
125
Taking Arvs     
51 patients
Already taking 
prior to admission
36
Started during 
admission 
15
Not taking Arvs  
74 patients
Awaiting 
implementation
63
Currently taking 
TB medication
11
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The average length of anti-retroviral use for the 36 patients that were 
already taking anti-retrovirals prior to admission was 9.81 months 
(SD=11.61). 
 
 4.4.3 Distribution of anti-retroviral medication 
 
Figure 4.9 exhibits the anti-retroviral medication used by the children 
taking anti-retroviral medication (n=51). 
 
 
 Figure 4.9 Distribution of anti-retroviral medication 
 
Nucleoside analogues such as Lamivudine and Stavudine were the 
most commonly prescribed drugs among ARV users. Abacavir (a first 
line drug) was used in 17.65% of patients on ARVs while Zidovudine 
and Didanosine were used in a small percent of patients (3.92% and 
1.96% respectively) as second line drugs. Kaletra was the protease 
inhibitor drug of choice (74.51%) with Ritonavir used in a small portion 
of patients (1.96%). Efavirenz was used as a non-nucleoside reverse 
transcriptase inhibitor in 19.61% of patients. Only one patient was still 
Distribution of anti-retroviral medication
Medication used
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taking neviripine and one patient was enrolled in another study which 
required administration of a “mystery drug”. 
 
4.4.4  Status of maternal anti-retroviral use during pregnancy (PMTCT) 
The breakdown of the status of anti-retroviral medication taken by the 
mothers during pregnancy is depicted in figure 4.10. 
 
________________________________________________________ 
Figure 4.10 Breakdown of the status of PMTCT use 
 
Of all the mothers there were only 31 (24.8%) who were involved in a 
PMTCT programme whereby approximately two thirds (67.7%) 
received either during pregnancy or labour or both. Ninety-four mothers 
were not involved in a PMTCT programme. 
4.5  Patient immune status 
 
 4.5.1 CD4 count and viral load values 
 
Information regarding the immunity of the children is included in table 
4.5.  
 
Mothers' s PMTCT 
status 
n=125 
Yes
n=31 
24.8% 
During Pregnancy
n=21
67.7%
During Labour
n=21
67.7%
No
n= 94
75.2%
Burden of Respiratory Disease in Paediatric Patients infected with HIV/AIDS 
N. da Cunha 
 
40    | P a g e  
 
Table 4.5 Immunological status  
 
 
Mean 
 
SD 
 
Median 
 
IQR 
CD4 percentage 17.33 10.96 16.7 8.94 – 21.3 
CD4 absolute (cell/mm3) 631.36 610.36 417 233.5 – 811.5 
Viral Load (copies/ mL)  2664420 9080406 350000 
   
33000 -  1550000 
            
*  SD  - standard deviation  
**  IQR – inter-quartile range 
 
The average CD4 count was 17.33% (SD=10.96) and 631.36 mm3 
(SD=610.36) while the average viral load was 2.6 million copies per mL 
(SD=9.1). 
 
4.5.2  Level of immunosuppression 
 
The level of immunosuppression was categorised into four stages 
(figure 4.11) according to the WHO staging which accounts for age and 
CD4 percentage (for children under 5 years) or CD4 absolute count (for 
children 5 years and older) . 
 
 
Figure 4.11 Level of immunosuppression 
17.76%
13.08%
13.08%
56.07%
Immunosuppression
Not significant
Mild
Advanced
Severe
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It is of importance to note that the immune status was assessed on the 
the basis of 107 patients’ results. Eighteen patients had missing CD4 
results. 
 
For the purpose of statistical analysis the advanced and severe 
categories were grouped together. The immunosupression distribution 
was thus modified (figure 4.12). 
 
 
  Figure 4.12 Modified level of immunosuppression 
 
 
4.6  Relationship between the burden of respiratory disease and 
the influencing factors 
 
 The burden of respiratory disease was regarded as low or high burden as 
described above. The influencing factors include: Anti-retroviral use, CD4 
count, viral load, age and gender. 
 
 A relationship was discovered with ARV use, CD4 count and gender (table 
4.6).   
 
No relationship was found with regard to viral load and age. 
 
17.76%
13.08%
69.16%
Immunosuppression - Modified
Not significant
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Advanced - Severe
Burden of Respiratory Disease in Paediatric Patients infected with HIV/AIDS 
N. da Cunha 
 
42    | P a g e  
 
 4.6.1  Logistic regression of burden versus ARV use 
  
With a crudes odd ratio of 0.54, it can be said that children not on 
ARVs have half the risk of having a higher burden of respiratory 
disease than children using ARVs.  
P value = 0.13. 
Therefore: there is a higher burden of disease among patients using 
anti-retrovirals – no statistical significance. 
 
 4.6.2  Logistic regression of burden of disease versus CD4 count 
 
With a crudes odd ratio of 1.66, it can be said that patients with a mild 
immunosuppression have one and a half times the risk of having a 
higher burden of respiratory disease than patients with a non-
significant immunosuppression. 
P value = 0.50. 
 
With a crudes odd ratio of 2.01, it can be said that patients with an 
advanced/severe immunosuppression have twice the risk of having a 
higher burden of respiratory disease than patients with a non-
significant immunosuppression. 
P value = 0.20 
Therefore: as the level of immunosuppression increases so does the 
burden of respiratory disease – with no statistical significance. 
 
 4.6.3  Logistic regression of burden of disease versus gender 
 
With a crudes odd ratio of 2.23, it can be said that females have twice 
the risk of having a higher burden of respiratory disease than males.  
P value = 0.05. 
Therefore: there is a higher burden of disease among female patients – 
with statistical significance. 
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These data are summarised in table 4.6 below. 
 
Table 4.6 Summary of findings 
 
 
Risk of increased 
Burden 
 
Crudes odd ratio 
 
P value 
ARV non -users 1/2 0.54 0.13 
Mild           
immunosuppression 
1 ½ 
 
1.66 0.50 
Advanced/Severe 
immunosuppression 
2 2.01 0.20 
Females 2 2.23 0.05 
 
 
4.7  Relationship between the burden of respiratory disease and 
the length of hospital stay 
  
 Using the Kaplan Meier survival curves there was a marginally significant 
difference (p= 0.06) between a low burden of disease and high burden with 
respect to mortality. 
 
o The low burden group died earlier but had a shorter length of stay 
o The high burden group died later but had a longer length of stay 
 
 The relationship between burden of disease and the length of hospital stay 
was also significant (p=0.029) significance was tested in various ways: 
o Students t test  p = 0.03 
o Welch t test   p ≤ 0.01 
o Mann-Whitney test  p=  0.03 
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 Therefore: the patients with a high burden of disease were admitted for longer 
and displayed incidents of mortality much later in admission compared to 
those with a low burden. 
 
4.8  Conclusion 
 
Of  the 125 patients recruited in this study 55% were boys and the mean age was 
20.55 months. The children stayed in hospital for an average of 2 ½ weeks, while 
80% were discharged and 9.6% died. The most common respiratory conditions 
presented included bacterial pneumonia (66.4%), tuberculosis (48%) and 
pneumocystis jirovecii pneumonia (23.2%). The least common condition was 
lymphoid interstitial pneumonitis (4.8%).  Two thirds of the children (68.8%) 
presented with more than one condition and thus a high burden of disease was more 
prevalent. Physiotherapy treatment was indicateded for 96% of the patients mainly 
due to excess secretions and poor air entry.  
 
 
The use of anti-retrovirals was 40.8%, while 50% were awaiting initiation. The 
average length of anti-retroviral use was 9.81 months. The most common drugs 
used were lamivudine, stavudine and kaletra. Seventy-five percent of mothers were 
not involved in a PMTCT program. The average CD4 % was 17.33, CD4 absolute 
631.36  cell/mm3 . The average viral load 2.6 million copies /ml. Thus most children 
presented in the advanced to severe group of immunosupression. There was a 
higher burden of disease among patients using anti-retrovirals (p=0.13), children with 
a mild level of immunosupression (p=0.50) and advanced to severe (p=0.20), and 
with female patients (0.05) and had a longer length of stay. 
 
These results will be discussed in the following chapter. 
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CHAPTER FIVE 
Discussion 
 
Introduction 
 
The results obtained in this study will be discussed in this chapter and comparisons 
will be made with previous studies. Clinical and research implications and challenges  
of this study are described. 
 
5.1 Demographics 
 
The study population consisted of 125 children all diagnosed with perinatally 
acquired HIV and a respiratory illness. Of all these children under the age of 
seven, the average age was found to be just short of two years. This study 
therefore included younger children compared to some other studies which 
were conducted on children with average ages of seven and a half years 
(Sheikh et al, 1997); five and a half years (Becciolini et al, 2001); two and a 
half years (Schaaf et al, 2007) and two years (Langston et al, 2008). The 
distribution of males to females was nearly the same.  
 
The length of hospital stay was approximately two and a half weeks and 
resulted in an 80% discharge rate. aMadhi et al (2000) found in a South 
African based study that the average length of hospitalisation was just under 
seven days. The mortality was found to be just under 10%. Similar results 
were found as in Jaspan et al (2008) with a nine percent mortality and greater 
mortality rates of 16% were found in a study by Ojikutu et al (2008) both of 
which were South African based studies. The large standard deviations are 
due to a wide range of results found in this study. 
 
Of the twelve patients who died only three (25%) were taking anti-retrovirals, 
however all three had only started during the study so essentially all children 
who died were ARV naive, highlighting the problems arising as a result of late 
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initiation of anti-retrovirals. Nine of the twelve children who died were under 
the age of six months, the other three were 15, 16 and 58 months old . Of the 
patients who died – Pneumonia, PJP, CMV Pneumonitis and TB were the 
associated respiratory illnesses, concurring with a 2004 Zambian study by 
Kouakoussui et al. 
 
5.2  Distribution of respiratory conditions in paediatric patients 
with HIV 
  
Although Zar (2008) discusses a shift from acute to chronic exacerbations of 
respiratory disease, this state is not clearly depicted in this study due to the 
population age of under seven and an average age of just under two. Perhaps 
then, this study may offer more insight into acute respiratory diseases. 
 
Pneumocystis Jirovecii Pneumonia varies between 10% and 17% of 
children according to Jeena (2005), however is represented by 23% of 
children in this study. It usually first causes infection early in childhood 
(Graham 2005). Graham (2003) reports that PJP presents with severe 
pneumonia, usually in infants between two and seven months old. This study 
supports this statement when looking at the age distribution of the children 
who presented with PJP. Of the twenty-nine children, 27 were seven months 
or younger. This demonstrates that PJP is one of the first presenting 
conditions in children with HIV and affects children at a very young age – 
supporting  the need for proper ante-natal HIV testing and PJP prophylaxis 
post-natally.  
With the current use of prophylaxis in the HIV clinics, this study further 
supports Graham‘s (2005) findings that bacterial pneumonia is now more 
common than PJP as an acute respiratory illness by almost three times as 
much. Lower respiratory tract infections (LRTI) are a major cause of morbidity 
and mortality in children aged under five years in developing countries 
(aMadhi et al, 2000; Zar et al, 2003). The average age of the children recruited 
in this study was just under two years. An immature immune system is a 
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factor which predisposes all children to infections and even more so due to 
the superimposed immunocompromised status.   
Bacterial Pneumonia was found in two thirds of all patients. This is a high 
level and recognises that community and nosocomial pneumonias are a more 
common presenting feature among HIV children especially since the 
management of other specific diseases such as PJP have become better 
controlled. CMV pneumonitis, often associated with PJP (Graham, 2003) 
was found in 18.4% of children in this study. 
 
Viral Pneumonia was not very common with only an eight percent 
presentation. This group included bronchiolitis and influenza viruses. Measles 
pneumonia was not seen in this group of patients. The swine flu epidemic 
occurred during this study. Despite low immunity among the study population, 
only two cases were diagnosed. The reasons for these values could indicate 
that perhaps this group in particular was not exposed to the swine flu and 
would not have taken into account the group of children that demised before 
the potential for admission. This group is still of importance to note as 
repeated viral infections may precipitate into chronic lung diseases of which 
HIV infected children are susceptible (Zar, 2008). 
 
In almost half of the cases Tuberculosis was a presenting respiratory 
disease. Tuberculosis is thus still a major factor in our country and its 
management should be of importance because co-infection with HIV results in 
more rapid deterioration of immune dysfunction, viral replication, and HIV 
progression and more frequently other severe infections (Zar, 2008).  
 
Tuberculosis has been associated as a co-infection in most HIV infected 
patients. The effects that TB has had in South Africa are vast. Diagnosis often 
requires a triad of investigations including chest xrays, skin tuberculin tests 
and sputum samples. Despite the use of these tests, some children still 
receive treatment in cases where the diagnosis is not confirmed. This is due 
to the nature of this epidemic – it is a prevalent community spread infection 
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that most children infected with HIV will be exposed to. It is therefore in the 
best interest of the children to receive TB treatment to reduce morbidity. This 
however impacts on the health budget as treatment is expensive as 
management should continue for at least six months and complications such 
as IRIS augments the need for health care.  
 
Lymphoid Interstitial Pneumonitis (LIP) is a common cause of chronic 
respiratory disease in HIV-infected African children (Graham, 2003). It is 
usually seen in children over the age of two years (Swigris et al, 2002). In this 
study a low percentage of cases was discovered – slightly less than five 
percent. This occurence may be due to a few reasons. Firstly the study 
population was young – under seven years old. Since LIP is considered a 
chronic lung disease it may be more prevalent in children over the age of 
seven. Of the six children presenting with LIP, the average age was 42 
months. The second reason may be due to improved care of acute respiratory 
exacerbations which long term may reduce the occurence of chronic lung 
diseases due to limited lung damage.  
Since the roll out of anti-retrovirals and improved knowledge regarding HIV 
and the respiratory system, the management of conditions presenting in the 
acute stage may be better than before. Another possible and likely reason for 
the low prevalence of LIP in this study group is the underdiagnosis of LIP as a 
result of an overdiagnosis of TB, since the presenting features are very 
similar. On xrays a diffuse reticulonodular pattern, more pronounced centrally 
is present which may be difficult to distinguish from pulmonary or miliary TB  
(Zar, 2008). 
 
Bronchiectasis is a common presenting condition among children infected 
with HIV and occurs as a result of repeated lung tissue damage. It occurs in 
up to 16% of children (Rabie et al, 2007). Just over eleven percent of children 
in this study presented with bronchiectasis. Sheikh et al (1997) report similar 
results however the children had a mean age of seven and a half years. This 
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recognises that the chronic lung diseases occur at a later age, maybe a 
reason for the relatively low numbers of children with bronchiectasis in this 
sample. 
 
5.3 Burden of disease  
 
The number of respiratory diseases presented was classified as low burden 
when only one condition was present and a high burden when two or more 
conditions were present. Due to the nature of the HIV disease and an 
increased susceptibility to infections – mixed infections are common such as 
bacterial pneumonia or cytomegalovirus (CMV) with PCP, or bacterial 
pneumonia complicating viral pneumonia, PTB, or LIP (Graham, 2003). This 
is clearly demonstrated in this study with a 68.8% rate of high disease burden.  
Other studies (Graham, 2005; Rabie et al, 2007) have not classified the 
burden of disease into low and high categories but have rather discussed the 
array of conditions with which each child presented – which are very similar to 
the conditions found in this study. Graham (2003) discusses the burden as the 
scale of the problem and the lack of resources specific to the African setting 
and Zar and Mulholland (2003) discuss how lower respiratory tract infections 
place a burden on  prevention and treatment. Zar and Mulholland (2003) also 
make references to other studies where the burden is described as the effect 
HIV has on mortality statistics. This study however has taken the burden of 
disease to signify the status of conditions presented and how they may co-
exist – which in effect is a factor leading to poor immune status and poor 
health.  
 
5.4 Indication for physiotherapy 
The indication for physiotherapy for each child was based upon the need to 
provide treatment due to excess secretions, decreased air entry, weak cough, 
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poor exercise endurance, poor positioning or posture, poor breathing control 
or need for a home programme and caregiver education in the event of 
chronic lung diseases (McClure, 1993).  
One hundred and twenty of the total number of patients (n=125) required 
physiotherapy mostly due to excess secretions and decreased air entry. Of 
the 120 patients the average indication for physiotherapy was thirteen days. 
There are no studies that have been done before to investigate the length of 
time that physiotherapy is required.  
Physiotherapy was provided to all children who required it, however the 
frequency or techniques used was dependent upon the physiotherapist 
working in the relevant wards and whether or not weekend physiotherapy was 
applied.  This could be viewed as an inconsistent variable which could affect 
the total number of days that a child would need physiotherapy based upon 
the efficacy of the physiotherapists’ treatments. However, it may also be 
viewed as a natural occurence that each physiotherapist will treat in a 
different manner, and thus the results are based upon research in a natural 
setting. 
 
5.5 Status of anti-retroviral use 
Of all the patients (n=125) only 36 were already taking anti-retrovirals prior to 
admission for an average length of 9.81 months (SD=11.61). Almost 60% of 
the children were not taking anti-retrovirals. Many patients are only diagnosed 
with HIV during a hospital admission – this accounts for 62 patients diagnosed 
with HIV but still awaiting the initiation of anti-retroviral drug treatment. The 
most commonly administrated drugs include: Stavudine, Lamivudine and 
Kaletra. These proportions may change as new combinations are attempting 
to lower drug toxicity. 
 
In 2010, the National Department of Health in South Africa published 
‘Guidelines for the Management of HIV in Children‘  and suggested that all 
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children under the age of one start anti-retrovirals immediately. Children 
between one and five years are eligible to start treatment if they are 
symptomatic stage III or IV, have a CD4 count under 750 cells/mm3 or 
percentage below 25%. Children over five may start ARV’s when they too are 
symptomatic of stage III or IV or their CD4 counts are below 350 cells/mm3. 
The 2004 guidelines from the National Department of Health were based on 
recurrent hospitalisations, a modified WHO stage II or III and CD4 
percentages under 20% for children under 18 months of age and under 15% 
for children over 18 months of age .  
Violari et al (2008) conducted a study which found that starting ARV’s at an 
average age of seven weeks reduced early mortality by 76% when compared 
to children receiving ARV’s based on CD4 percentage or clinical progression 
of HIV. Studies show that early anti-retroviral treatment initiation reduces the 
risk of opportunistic infections and lowers the viral load (Kouakoussui, et al. 
2004; Eley et al. 2006).  The initiation of early anti-retrovirals has shown a 69-
94% reduction in mortality (Kitahata et al, 2009) and Boulle et al (2008) 
showed that ARV’s reduced early mortality rates within the first six months. 
Ojikutu et al (2008) found that the strongest predictors of mortality in children 
who have initiated anti-retroviral drugs are CD4 counts less than 50 and the 
presence of oral candidiasis.  
 
Anti-retroviral drugs were introduced to South Africa in 2004 and since the 
children recruited in the study are under the age of seven, most were born in 
the post-HAART era. Despite this, a low number of children were on 
treatment. Perhaps then, there are still many problems facing HIV testing and 
anti-retroviral initiation. The identification of actively replicating virus by DNA 
polymerase chain reaction (PCR) is more reliable, but is difficult to obtain in 
most developing countries. Replication of this study in a few years may yield 
different results since the new 2010 revised guidelines on anti-retroviral 
treatment will recruit more patients into the anti-retroviral programme. 
 
Burden of Respiratory Disease in Paediatric Patients infected with HIV/AIDS 
N. da Cunha 
 
52    | P a g e  
 
5.6 Prevention of mother to child transmission 
Of all the mothers just under a quarter (24.8%) took anti-retrovirals during 
pregnancy. Of the infected children in this study it is shown that despite a 
quarter of the mothers undergoing PMTCT, their children tested positive. This 
identifies that the PMTCT programme is not yet reaching all settings in South 
Africa as there were many mothers who did not join the PMTCT programme. 
Ante-natal care should be widely promoted and PMTCT programmes need to 
be carefully monitored in order to reduce transmission rates.   
 
The proportion of current maternal anti-retroviral use was not evaluated, 
however it is an important factor influencing the burden of childhood disease – 
with regard to administration of medication to children, nutrition, spread of 
disease and mortality. Maternal death is a major risk factor for poor survival in 
HIV-exposed infants (Graham, 2005). Seven intervention trials from sub-
Saharan Africa in largely breastfeeding populations demonstrated that the 
death of children by age one is approximately seven times greater when the 
mothers are HIV infected compared to non-infected (Newell et al, 2004).  
 
5.7 Patient immune status 
The average CD4 count was 17.33% and 631.36 mm3, while the average viral 
load was 2.6 million copies/ml. This places almost 70% of the study 
population in the advanced to severe immune-compromised group. This 
directly increases the burden of respiratory disease which in turn impacts on 
the health system and need for hospital care.  
 
Identifying the immune status is important for the initiation of anti-retroviral 
drugs. As seen in this study their immune systems are compromised and thus 
most children would classify for drug initiation – as discussed above with 
regard to CD4 counts and percentages being eligibility criteria for the initiation 
of anti-retrovirals. The results with regard to immune status are only based on 
107 children as not all viral load and CD4 counts were tested.  
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5.8  Relationship between the burden of respiratory disease and 
the influencing factors 
 
This study set out to determine whether there was a relationship between the 
burden of respiratory disease and a variety of factors. No relationship was 
found with regard to viral load and age. However a relationship was found 
pertaining to the use of anti-retrovirals, level of immune suppression and 
gender. 
 
Despite statistical significance as the p value was higher than 0,05, the study 
found that there was a higher burden of disease among patients using anti-
retroviral medication. Although statistically this result has no bearing it does 
have clinical relevance. This result seems to be contradictory as the use of 
anti-retrovirals should improve the immune status and thus reduce the 
incidence of respiratory disease. The results found in this study may be due to 
a few reasons. The fact that some of the children were receiving anti-
retrovirals did not distinguish those whom were on the drugs for a short period 
in which the effects have not yet taken place. It may also be that the children 
presenting with more conditions have been referred to the tertiary hospitals by 
secondary or primary institutions for more specialised care of complicated 
conditions – and thus already may have initiated anti-retrovirals at an earlier 
age.  
 
There was a relationship between the level of immune suppression and the 
burden of disease. As the level of immunity decreases indicated by a 
reduction in the CD4 percentage or absolute value, children are more 
predisposed to infection or acquiring respiratory conditions. A study has 
discussed that the CD4 T cell determines host susceptibility to PCP in some 
animal models (Beck et al, 2001) and that it may also induce inflammation, 
lung injury and death.  
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The results did show that as the immune suppression changed from mild to 
advanced/severe, the risk of a high burden of disease increased from one and 
a half times (crudes odds ratio = 1.66) to two times (crudes odds ratio = 2.01) 
the risk. This is clinically relevant. Therefore as the immunity decreases it may 
be said that the burden of respiratory disease increases. Children infected 
with HIV have a lower immunity and are thus more susceptible to more 
infections and even more so to having a number of co-existing conditions. 
 
With regard to gender the results show that girls are twice as likely to develop 
a higher burden of disease than boys. This contrasts with the findings by 
Kristensen et al (2006) that girls tended to be better protected against acute 
respiratory infections than boys. They studied a sample of children in Soweto 
who had an estimated HIV infection rate of five to six percent. There are no 
other studies that have looked at the difference between boys and girls with 
regard to the burden of disease and the distribution of respiratory conditions 
presented. 
 
 
5.9  Relationship between the burden of respiratory disease and 
the length of hospital stay 
 
The study sought to find if there was a relationship between the burden of 
disease and the length of hospital stay and with respect to mortality. With 
regard to mortality the children with a low burden of disease, that is with one 
condition, died at earlier stages of hospital admission. The patients with a high 
burden of disease were admitted for longer and displayed incidents of 
mortality much later in admission compared to those with a low burden.  
 
There may be more than one reason for these findings. Of the children who 
died (n=12), nine were under the age of six months. Children who were 
admitted with only one condition such as pneumocystis jirovecii pneumonia 
which is severe in its presentation, may not have had enough time for 
adequate care and thus demised at an early stage of admission. The children 
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identified to have a higher burden of disease may have received a more 
intense program of care and thus their length of hospital stay was longer.  
 
There was no relationship between the age of the child and the point of 
hospital stay when mortality occurred - the children who died earlier were not 
necessarily younger. Mortality was rather influenced by the number of 
conditions presented. 
 
5.10 Challenges 
 
The study chose to include children under the age of seven years. This has 
therefore not included a population of children who would have presented with 
more chronic lung diseases. This is seen with a low number of cases of LIP 
and bronchiectasis in this study. The study has therefore only given an idea of 
the burden of acute respiratory conditions. 
 
The conditions presented were extracted from patient’s files – the accuracy of 
the diagnosis was therefore out of the researcher’s control. 
 
Since the study recruited data from two tertiary hospitals the indication for 
physiotherapy may have been affected by factors which were uncontrollable. 
Physiotherapists recruit a variety of treatment strategies and frequencies of 
treatment. 
 
This study did not distinguish the length of ARV use as a factor towards the 
development of a high burden of respiratory disease but rather whether the 
child was on treatment or not. Therefore the study demonstrated that the use 
of anti-retrovirals does not necessarily protect a child from developing a high 
burden of respiratory conditions – perhaps the length of use does. 
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5.11 Clinical and research implications 
  
The average length of hospital stay was two and a half weeks which could be 
due to a number of reasons for prolonged care. It is however a risk for 
hospital acquired infections. It is also important to consider that this study 
recruited a sample of children under seven years of age with an average of 
20.55 months of age (SD=23.64). This sample therefore is a vulnerable group 
with regard to acquiring respiratory infections, with age as a factor alone. HIV 
predisposes these children to be more susceptible. While this study has 
looked at the respiratory disease profile and its contributing factors in children 
infected with HIV, it might be interesting to conduct a comparison study 
between children infected and non-infected of the same age within the same 
setting.  
 
 PJP has shown to be less prevalent than before and is now less common 
than bacterial pneumonia. This has shown that efforts to introduce PJP 
prophylaxis has worked. The fact that PJP continues to contribute towards 
early mortality in the younger children recognises that the ante-natal 
prophylaxis programme is still not optimal. 
 
This study assessed the burden of respiratory disease with regard to the 
respiratory conditions presented and the effects that ARV use, CD4 counts 
and gender have. This is in contrast to other studies whereby the burden of 
disease was assessed by looking at the mortality rates alone. This therefore 
has presented data on the clinical features of children infected with HIV 
admitted to hospital. As the guidelines for anti-retroviral eligibility change and 
ante-natal testing improves – future studies may yield different results and the 
profile of respiratory diseases may be quite different.   
 
A high burden of disease was clearly demonstrated with a 68,8% rate and this 
supports the indication for physiotherapy. Future studies may investigate 
which modalities and intensities of treatment are better suited to each 
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condition and thus further improve clinical understanding among 
physiotherapists treating children with HIV related respiratory conditions. 
 
With an average age of just under two of all patients recruited, the study found 
that almost 60% of children were not on anti-retroviral therapy. This indicates 
that widespread testing during early infancy is not yet optimal. Similarly, the 
PMTCT program may not yet be as effective as just under a quarter of the 
mothers were involved in a PMTCT program and still transmitted the virus to 
their children. 
Almost 70% of the study participants were placed in the advanced to severe 
immune-compromised group and thus our health care settings particularly 
tertiary institutions are dealing with a vulnerable group that requires 
specialised care. Since the immune suppression influenced the risk of the 
burden of respiratory disease it is important that the clinical profile of children 
be evaluated regularly to identify children most at risk. The intervention given 
by physiotherapists may then be influenced by identifying those patients most 
at risk quicker. This study has established basic characteristics of the 
respiratory disease burden among hospitalised children with HIV in a South 
African setting in a post HAART era. 
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CHAPTER SIX 
Conclusion 
 
The aim of the study was to determine the burden of disease with regard to 
the prevalence of respiratory conditions among paediatric patients infected 
with HIV/AIDS and to establish the indication for chest physiotherapy. The 
product of this study investigated the burden of respiratory disease with a 
focus on acute exacerbations due to the age group selected. Of the 125 
children perinatally infected with HIV, there was just under a 10% mortality 
rate owing predominantly to children diagnosed with Pneumonia, PJP, CMV 
Pneumonitis and TB. Conditions observed were similar to previous studies, 
highlighting that PJP, bacterial and viral pneumonia, TB, LIP, CMV 
pneumonitis and bronchiectasis remain common conditions among children 
with HIV. A shift seen in recent years as described in this study is that 
bacterial pneumonia has overtaken PJP as the leading respiratory condition 
due to improved prophylactic measures. A large majority of patients presented 
with an indication for physiotherapy treatment, which highlights the 
importance of physiotherapists understanding this population of patients.  
 
 With regard to the relationships between the burden of disease and the 
influencing factors, it was found that a higher burden of disease was related to 
the use of anti-retrovirals, a higher immuno-suppression, female patients, 
longer length of stay and later mortality rates. Despite six years of anti-
retroviral therapy roll-out there are still so many undiagnosed children who 
await initiation and thus in the interim, many respiratory conditions still prevail. 
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Appendix IV: Consent from superintendants to conduct research at Steve Biko 
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Appendix V: Data collection form 
 
Entry number     ______________________________ 
Date of Admission    ______________________________ 
Age      Years _________ Months ________ 
Gender     Male _________  Female  _______ 
Status of Current ARV therapy   Yes     _________   No  _________ 
Drug combinations used   ________________________________ 
      ________________________________ 
      ________________________________ 
Length of drug use in months  ___________________________ 
Status of Previous ARV therapy   Yes     _________   No  _________ 
Drug combinations used   ________________________________ 
      ________________________________ 
Mother’s ARV use                                    ________________________________ 
      ________________________________ 
Patient’s CD4 count    ___________________________ 
Viral load     ___________________________ 
Length of Hospital Stay in days  __________ 
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Appendix VI: Information sheet for caregivers 
 
Information Sheet for Caregivers 
 
Screening for the need of Chest Physiotherapy among Paediatric patients infected with 
HIV/AIDS  
 
Dear Caregiver, 
Thank you very much for taking the time to read this letter. 
 
My name is Natalia da Cunha, I am a physiotherapist and I am doing research on children 
infected with HIV who also have lung illnesses. Research is the way that people, like me, 
working in the hospital can find the answer to a question about the patients’ health. 
Physiotherapy can help with most lung illnesses because it can help loosen the secretions 
and help your child cough. This can be done by giving your child inhalations, clapping over 
the chest, vibrations and suctioning or assisted coughing, exercise and positioning correctly 
to improve the way your child breaths.  In this study I want to learn what illness is affecting 
your child’s lungs. This will help me understand the different illnesses that all the children 
have. I would like to learn this so that I, as a physiotherapist, can see which children need 
physiotherapy. I want to learn this from children with HIV because children with HIV have 
more chance of getting a lung illness. The answer to the question will help me or any other 
physiotherapist working with these children make sure that the children needing 
physiotherapy will receive it as soon as possible. 
I am asking for your permission so that I can include your child in the research study. If you 
give me permission, then I would like to read the child’s hospital file and then write down 
information that I can then use to find the answer to my question.  
The child’s name will not be used at all and I will not tell any person which children are part 
of the study. Only the child’s hospital number will be written so that I do not mix the papers, 
but once I have added up all the results these papers will be destroyed.  
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No procedures will be done to your child except for normal physiotherapy if needed. As no 
procedures will be done there are no risks and no benefits involved if your child takes part in 
the study. 
Participation in the study is voluntary – only if you want to. Physiotherapy is part of normal 
treatment for your child and should you not want to give permission for your child to take part 
in the study, your child will not be treated differently and will still receive normal 
physiotherapy treatment.  
You will not be paid should your child be part of the study. 
The Research Ethics Committee from the University of Witwatersrand and University of 
Pretoria have approved the study and will monitor the quality of the study. 
You are encouraged to ask any questions throughout the study and if you would like to see 
the results of the study you are welcome to ask for them.  
Please feel free to contact me 072 465 4711 
 
Miss Natalia da Cunha 
Physiotherapist 
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Appendix VII: Consent form 
Consent documents for Caregivers 
 
Title of Research: Screening for the need of Chest Physiotherapy among Paediatric patients 
infected with HIV/AIDS  
 
I, the caregiver of the child, have read the attached information sheet and 
understand the procedure of the study and what is required of me. I understand that I 
am free to refuse or to withdraw my consent and discontinue the child’s participation 
any time. I have had due chance to query any additional information and have had a 
reply. I understand that if I have any more questions at any time they will be 
answered.  By refusing to take part in this study I understand that the child’s 
treatment received in the hospital will not be affected.  I also understand that I will 
not get paid for taking part in this study, and that the child’s name will be kept 
confidential. 
 
Entry number: _____________ 
 
Caregiver: 
 
Signiture: ____________ Print name:________________ Date: ___________ 
 
Witness : 
 
Signiture: ____________ Print name:________________ Date: ___________ 
 
Investigator : 
 
Signiture: ____________ Print name:________________ Date: ___________ 
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Verbal Informed Consent 
 
I, the undersigned, have read and have fully explained the information leaflet, which explains 
the nature and process of the study to the caregiver whom I have asked to provide consent 
for their child to partake in the study. 
 
The caregiver indicates that s/he understands that the results of the study, including 
personal details will be anonymously processed into a research report. The caregiver 
indicates that s/he has had time to ask questions and has no objection to the inclusion of 
his/her child’s medical information in the study. 
S/he understands that should s/he wish to withdraw from the study the patient’s treatment in 
hospital will not be affected in any way. I hereby certify that the caregiver has agreed to 
provide consent for the child to participate in the study. 
 
Entry number: _____________ 
 
Caregiver: 
Signiture: ____________ Print name:________________ Date: ___________ 
 
Witness : 
Signiture: ____________ Print name:________________ Date: ___________ 
 
Investigator : 
Signiture: ____________ Print name:________________ Date: ___________ 
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Appendix VIII: Guidelines for the indication of physiotherapy treatment 
 
